Advertisement

Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Document › Details

Exact Therapeutics AS. (1/26/21). "Press Release: Exact Therapeutics Announces Appointment of Dr Hilary McElwaine-Johnn as Chief Medical Officer and Opening of London Office". Oslo & London.

Region Region London, Greater London
  Country United Kingdom (GB)
Organisations Organisation Exact Therapeutics AS
  Organisation 2 Exact Therapeutics AS, London Office
  Group Exact Therapeutics AS
Products Product Acoustic Cluster Therapy (ACT® sonoporation)
  Product 2 oncology
Persons Person Hayhurst, Richard (Hayhurst Media 200705)
  Person 2 Hasan, Rafiq (Exact Therapeutics 202006– CEO before Bayer + Novartis)
     


EXACT THERAPEUTICS AS (“EXACT-Tx” or the “Company”), a clinical stage precision medicine company utilizing Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today announced the appointment of Dr Hilary McElwaine-Johnn as Chief Medical Officer. Dr McElwaine-Johnn will be based at the newly opened London office of EXACT-Tx at the Translation & Innovation Hub (i-Hub) at White City.

“We are delighted to welcome Hilary to EXACT Therapeutics AS where her unique experience in both therapeutics and drug delivery complemented by deep medical expertise will be pivotal in driving forward the development of ACT®, both in the ongoing Phase I ACTIVATE study and beyond”,

said Dr Rafiq Hasan, CEO of EXACT Therapeutics AS.

“Hilary joins EXACT-Tx at an exciting time as we expand our presence in the UK with the opening of our London office at the White City i-Hub in close proximity to the growing Imperial College campus”.

Dr McElwaine-Johnn gained her medical degree from Imperial College, London and is a Member of the Royal College of Physicians and Faculty of Pharmaceutical Medicine. Following clinical roles in general internal medicine and oncology, she has pursued a highly successful career in the pharmaceutical industry. She has held a variety of senior medical positions including Vice President, Clinical, PowderMed Ltd (which was subsequently acquired by Pfizer), Chief Medical Officer of Vantia Ltd, PsiOxus Therapeutics Ltd and most recently Karus Therapeutics. During this time Hilary has gained extensive experience in drug development in both oncology and other therapeutic indications as well as delivery technologies complemented by a range of successful interactions with Regulatory Authorities, partner companies and fundraising activities.

Dr McElwaine-Johnn commented:

“I am excited to be joining EXACT Therapeutics in London to be part of a dynamic and innovative organization exploring the potential of the ACT® platform to transform clinical practice across indications, particularly in the management of patients with cancer. With a strong preclinical evidence base and clinical development of ACT® already underway, I am looking forward to working with the clinical community in further investigating this exciting approach to ultrasound mediated therapeutic targeting.”


About ACT®

• ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent.

ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration.

• Initial focus of the company is oncology, however the ACT® platform has potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes.


About EXACT

EXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com


For more information contact:

Dr Rafiq Hasan
CEO EXACT Therapeutics
Rafiq@exact-tx.com

Richard Hayhurst/Janet Joy
Tel +44 7711 821527
richard@rhapr.eu

   
Record changed: 2021-02-06

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Exact Therapeutics AS


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe Spring 2021 Digital 650x80




» top